ALT
Altimmune, Inc.
Price Chart
Latest Quote
$5.55
Current Price| Previous Close | $5.60 |
| Open | $5.60 |
| Day High | $5.75 |
| Day Low | $5.26 |
| Volume | 5,164,235 |
Stock Information
| Shares Outstanding | 125.23M |
| Total Debt | $15.90M |
| Cash Equivalents | $210.78M |
| Revenue | $20K |
| Net Income | $-83.92M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $695.03M |
| EPS (TTM) | $-1.07 |
| Exchange | NGM |
đ Custom Metrics & Score
Score: 14/42| Debt to Equity | 0.01 |
| Debt to Earnings | -0.02 |
| Current Ratio | 13.11 |
| Quick Ratio | 12.90 |
| Avg Revenue Growth | -24.89% |
| Profit Margin | -475295.00% |
| Return on Equity | -76.97% |
| Avg FCF Growth | -2.95% |
| FCF Yield | -11.49% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $5.55 | 5,172,200 |
| 2026-01-30 | $5.60 | 6,280,800 |
| 2026-01-29 | $5.10 | 4,089,500 |
| 2026-01-28 | $5.12 | 13,080,000 |
| 2026-01-27 | $6.18 | 5,788,700 |
| 2026-01-26 | $5.66 | 5,736,700 |
| 2026-01-23 | $5.50 | 15,507,200 |
| 2026-01-22 | $5.38 | 8,195,000 |
| 2026-01-21 | $4.62 | 3,909,200 |
| 2026-01-20 | $4.23 | 4,516,600 |
| 2026-01-16 | $4.24 | 2,598,200 |
| 2026-01-15 | $4.24 | 4,554,000 |
| 2026-01-14 | $4.18 | 3,266,500 |
| 2026-01-13 | $4.01 | 2,604,200 |
| 2026-01-12 | $4.05 | 2,763,800 |
| 2026-01-09 | $4.02 | 3,075,200 |
| 2026-01-08 | $4.08 | 3,843,100 |
| 2026-01-07 | $4.19 | 7,287,300 |
| 2026-01-06 | $3.96 | 5,650,600 |
| 2026-01-05 | $4.09 | 27,007,100 |
About Altimmune, Inc.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
đ° Latest News
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development
Insider Monkey âĸ 2026-02-02T14:55:40Z
Why Altimmune (ALT) Is Up 29.7% After FDA Breakthrough Tag For Obesity-MASH Drug - And What's Next
Simply Wall St. âĸ 2026-01-25T11:09:01Z
Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly
24/7 Wall St. âĸ 2026-01-23T19:06:34Z
Unusually active option classes on open January 22nd
TipRanks âĸ 2026-01-23T14:40:28Z
Altimmune (ALT) Is Up 13.0% After FDA Breakthrough Tag For Pemvidutide In MASH - Has The Bull Case Changed?
Simply Wall St. âĸ 2026-01-09T03:15:31Z
ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH
Zacks âĸ 2026-01-06T16:53:00Z
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround
Zacks âĸ 2025-12-29T15:15:00Z
Jerome Durso Buys Handful Of Shares In Altimmune
Simply Wall St. âĸ 2025-12-28T12:33:42Z
Does Altimmune (ALT) Have the Potential to Rally 229.28% as Wall Street Analysts Expect?
Zacks âĸ 2025-12-11T14:55:02Z
Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's What You Should Know
Zacks âĸ 2025-11-25T14:55:03Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $20,000 | $426,000 | $-68,000 | $4,410,000 |
| Operating Revenue | $20,000 | $426,000 | $-68,000 | $4,410,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $9,000 | $35,000 | $8,000 | $5,000 |
| Total Expenses | $103,192,000 | $83,936,000 | $87,672,000 | $89,954,000 |
| Other Income Expense | $48,000 | $-12,253,000 | $-32,000 | $-11,744,000 |
| Other Non Operating Income Expenses | $48,000 | $166,000 | $-32,000 | $-374,000 |
| Net Non Operating Interest Income Expense | $8,065,000 | $7,316,000 | $2,862,000 | $198,000 |
| Interest Expense Non Operating | $9,000 | $35,000 | $8,000 | $5,000 |
| Operating Expense | $103,192,000 | $83,936,000 | $87,672,000 | $89,954,000 |
| General And Administrative Expense | $20,966,000 | $18,137,000 | $17,134,000 | $15,413,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-95,059,000 | $-88,447,000 | $-84,713,000 | $-97,090,000 |
| Net Interest Income | $8,065,000 | $7,316,000 | $2,862,000 | $198,000 |
| Interest Income | $8,074,000 | $7,351,000 | $2,870,000 | $203,000 |
| Normalized Income | $-95,059,000 | $-76,028,000 | $-84,713,000 | $-85,720,000 |
| Net Income From Continuing And Discontinued Operation | $-95,059,000 | $-88,447,000 | $-84,713,000 | $-97,090,000 |
| Total Operating Income As Reported | $-103,172,000 | $-95,929,000 | $-87,740,000 | $-96,914,000 |
| Net Income Common Stockholders | $-95,059,000 | $-88,447,000 | $-84,713,000 | $-97,090,000 |
| Net Income | $-95,059,000 | $-88,447,000 | $-84,713,000 | $-97,090,000 |
| Net Income Including Noncontrolling Interests | $-95,059,000 | $-88,447,000 | $-84,713,000 | $-97,090,000 |
| Net Income Continuous Operations | $-95,059,000 | $-88,447,000 | $-84,713,000 | $-97,090,000 |
| Pretax Income | $-95,059,000 | $-88,447,000 | $-84,910,000 | $-97,090,000 |
| Special Income Charges | $0 | $-12,419,000 | $0 | $-11,370,000 |
| Interest Income Non Operating | $8,074,000 | $7,351,000 | $2,870,000 | $203,000 |
| Operating Income | $-103,172,000 | $-83,510,000 | $-87,740,000 | $-85,544,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-1.34 | $-1.66 | $-1.81 | $-2.35 |
| Basic EPS | $-1.34 | $-1.66 | $-1.81 | $-2.35 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-94,812,000 | $-75,516,000 | $-84,409,000 | $-85,164,000 |
| Total Unusual Items | $0 | $-12,419,000 | $0 | $-11,370,000 |
| Total Unusual Items Excluding Goodwill | $0 | $-12,419,000 | $0 | $-11,370,000 |
| Reconciled Depreciation | $238,000 | $477,000 | $493,000 | $551,000 |
| EBITDA (Bullshit earnings) | $-94,812,000 | $-87,935,000 | $-84,409,000 | $-96,534,000 |
| EBIT | $-95,050,000 | $-88,412,000 | $-84,902,000 | $-97,085,000 |
| Diluted Average Shares | $71,003,399 | $53,246,937 | $46,926,349 | $41,283,498 |
| Basic Average Shares | $71,003,399 | $53,246,937 | $46,926,349 | $41,283,498 |
| Diluted NI Availto Com Stockholders | $-95,059,000 | $-88,447,000 | $-84,713,000 | $-97,090,000 |
| Impairment Of Capital Assets | $0 | $12,419,000 | $0 | $11,370,000 |
| Research And Development | $82,226,000 | $65,799,000 | $70,538,000 | $74,541,000 |
| Selling General And Administration | $20,966,000 | $18,137,000 | $17,134,000 | $15,413,000 |
| Other Gand A | $20,966,000 | $18,137,000 | $17,134,000 | $15,413,000 |
| Tax Provision | - | $0 | $-197,000 | $0 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $123,508,000 | $194,099,000 | $172,874,000 | $186,716,000 |
| Total Assets | $139,306,000 | $210,640,000 | $206,928,000 | $218,865,000 |
| Total Non Current Assets | $2,052,000 | $1,014,000 | $14,115,000 | $14,739,000 |
| Other Non Current Assets | $1,639,000 | $363,000 | $615,000 | $872,000 |
| Current Assets | $137,254,000 | $209,626,000 | $192,813,000 | $204,126,000 |
| Other Current Assets | $2,204,000 | $6,917,000 | $5,358,000 | $7,952,000 |
| Restricted Cash | $42,000 | $41,000 | $34,000 | $34,000 |
| Receivables | $3,117,000 | $4,853,000 | $2,541,000 | $5,839,000 |
| Taxes Receivable | $2,573,000 | $3,742,000 | $2,368,000 | $5,410,000 |
| Accounts Receivable | $544,000 | $1,111,000 | $173,000 | $429,000 |
| Cash Cash Equivalents And Short Term Investments | $131,891,000 | $197,815,000 | $184,880,000 | $190,301,000 |
| Cash And Cash Equivalents | $36,926,000 | $135,117,000 | $111,097,000 | $190,301,000 |
| Goodwill And Other Intangible Assets | - | $0 | $12,419,000 | $12,419,000 |
| Other Intangible Assets | - | - | $12,419,000 | $12,419,000 |
| Prepaid Assets | - | - | - | $7,952,690 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $1,681,000 | $671,000 | $1,124,000 | $1,535,000 |
| Long Term Debt And Capital Lease Obligation | $1,402,000 | $175,000 | $672,000 | $1,124,000 |
| Current Debt And Capital Lease Obligation | $279,000 | $496,000 | $452,000 | $411,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $15,798,000 | $16,541,000 | $21,635,000 | $19,730,000 |
| Total Non Current Liabilities Net Minority Interest | $5,330,000 | $4,398,000 | $4,581,000 | $1,454,000 |
| Other Non Current Liabilities | $3,928,000 | $4,223,000 | $3,909,000 | $330,000 |
| Current Liabilities | $10,468,000 | $12,143,000 | $17,054,000 | $18,276,000 |
| Payables And Accrued Expenses | $10,189,000 | $11,647,000 | $16,602,000 | $11,775,000 |
| Interest Payable | $55,000 | $124,000 | $103,000 | $44,000 |
| Payables | $211,000 | $2,070,000 | $5,973,000 | $2,034,000 |
| Accounts Payable | $211,000 | $2,070,000 | $4,804,000 | $2,034,000 |
| Total Tax Payable | - | $0 | $1,169,000 | $0 |
| Other Current Liabilities | - | - | - | $6,090,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $123,508,000 | $194,099,000 | $185,293,000 | $199,135,000 |
| Total Equity Gross Minority Interest | $123,508,000 | $194,099,000 | $185,293,000 | $199,135,000 |
| Stockholders Equity | $123,508,000 | $194,099,000 | $185,293,000 | $199,135,000 |
| Gains Losses Not Affecting Retained Earnings | $-4,973,000 | $-5,004,000 | $-5,227,000 | $-5,040,000 |
| Other Equity Adjustments | $-4,973,000 | $-5,004,000 | $-5,227,000 | $-5,040,000 |
| Retained Earnings | $-561,390,000 | $-466,331,000 | $-377,884,000 | $-293,171,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $72,352,701 | $70,677,400 | $49,199,845 | $40,993,768 |
| Share Issued | $72,352,701 | $70,677,400 | $49,199,845 | $40,993,768 |
| Tangible Book Value | $123,508,000 | $194,099,000 | $172,874,000 | $186,716,000 |
| Invested Capital | $123,508,000 | $194,099,000 | $185,293,000 | $199,135,000 |
| Working Capital | $126,786,000 | $197,483,000 | $175,759,000 | $185,850,000 |
| Capital Lease Obligations | $1,681,000 | $671,000 | $1,124,000 | $1,535,000 |
| Total Capitalization | $123,508,000 | $194,099,000 | $185,293,000 | $199,135,000 |
| Additional Paid In Capital | $689,864,000 | $665,427,000 | $568,399,000 | $497,342,000 |
| Capital Stock | $7,000 | $7,000 | $5,000 | $4,000 |
| Common Stock | $7,000 | $7,000 | $5,000 | $4,000 |
| Long Term Capital Lease Obligation | $1,402,000 | $175,000 | $672,000 | $1,124,000 |
| Current Capital Lease Obligation | $279,000 | $496,000 | $452,000 | $411,000 |
| Current Accrued Expenses | $9,978,000 | $9,577,000 | $10,629,000 | $9,741,000 |
| Net PPE | $413,000 | $651,000 | $1,081,000 | $1,448,000 |
| Accumulated Depreciation | $-2,213,000 | $-1,975,000 | $-1,498,000 | $-2,047,000 |
| Gross PPE | $2,626,000 | $2,626,000 | $2,579,000 | $3,495,000 |
| Leases | $1,749,000 | $1,749,000 | $1,749,000 | $1,794,000 |
| Other Properties | $342,000 | $342,000 | $295,000 | $1,040,000 |
| Machinery Furniture Equipment | $535,000 | $535,000 | $535,000 | $661,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $94,965,000 | $62,698,000 | $73,783,000 | $0 |
| Treasury Shares Number | - | $0 | - | - |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-79,848,000 | $-75,857,000 | $-62,712,000 | $-90,550,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-79,848,000 | $-75,810,000 | $-62,586,000 | $-78,238,000 |
| Cash Flow From Continuing Operating Activities | $-79,848,000 | $-75,810,000 | $-62,586,000 | $-78,238,000 |
| Operating Gains Losses | $-48,000 | $-154,000 | $34,000 | $384,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Investing Cash Flow | $-28,386,000 | $13,732,000 | $-73,399,000 | $87,523,000 |
| Cash Flow From Continuing Investing Activities | $-28,386,000 | $13,732,000 | $-73,399,000 | $87,523,000 |
| Capital Expenditure | - | $-47,000 | $-126,000 | $-12,312,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $9,994,000 | $86,601,000 | $56,347,000 | $65,040,000 |
| Financing Cash Flow | $10,044,000 | $86,105,000 | $56,781,000 | $65,098,000 |
| Cash Flow From Continuing Financing Activities | $10,044,000 | $86,105,000 | $56,781,000 | $65,098,000 |
| Net Other Financing Charges | $-850,000 | $-824,000 | $-516,000 | $-118,000 |
| Net Common Stock Issuance | $9,994,000 | $86,601,000 | $56,347,000 | $65,040,000 |
| Common Stock Issuance | $9,994,000 | $86,601,000 | $56,347,000 | $65,040,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| End Cash Position | $36,968,000 | $135,158,000 | $111,131,000 | $190,335,000 |
| Beginning Cash Position | $135,158,000 | $111,131,000 | $190,335,000 | $115,952,000 |
| Changes In Cash | $-98,190,000 | $24,027,000 | $-79,204,000 | $74,383,000 |
| Proceeds From Stock Option Exercised | $900,000 | $328,000 | $950,000 | $176,000 |
| Net Investment Purchase And Sale | $-28,386,000 | $13,779,000 | $-73,273,000 | $99,835,000 |
| Sale Of Investment | $87,345,000 | $102,410,000 | $0 | $107,427,000 |
| Purchase Of Investment | $-115,731,000 | $-88,631,000 | $-73,273,000 | $-7,592,000 |
| Net PPE Purchase And Sale | $0 | $-47,000 | $-126,000 | $-12,117,000 |
| Purchase Of PPE | $0 | $-47,000 | $-126,000 | $-12,117,000 |
| Change In Working Capital | $4,478,000 | $-8,274,000 | $14,111,000 | $-251,000 |
| Change In Payables And Accrued Expense | $-1,971,000 | $-4,617,000 | $8,163,000 | $-877,000 |
| Change In Accrued Expense | $-112,000 | $-1,883,000 | $5,393,000 | $-2,299,000 |
| Change In Payable | $-1,859,000 | $-2,734,000 | $2,770,000 | $1,422,000 |
| Change In Account Payable | $-1,859,000 | $-2,734,000 | $2,770,000 | $1,422,000 |
| Change In Prepaid Assets | $4,713,000 | $-1,345,000 | $2,650,000 | $-5,908,000 |
| Change In Receivables | $1,736,000 | $-2,312,000 | $3,298,000 | $6,534,000 |
| Changes In Account Receivables | $567,000 | $-938,000 | $256,000 | $4,181,000 |
| Stock Based Compensation | $14,393,000 | $10,640,000 | $8,101,000 | $5,519,000 |
| Asset Impairment Charge | $0 | $12,419,000 | $0 | $11,949,000 |
| Amortization Of Securities | $-3,850,000 | $-2,471,000 | $-698,000 | - |
| Depreciation Amortization Depletion | $238,000 | $477,000 | $493,000 | $551,000 |
| Depreciation And Amortization | $238,000 | $477,000 | $493,000 | $551,000 |
| Depreciation | $238,000 | $477,000 | $493,000 | - |
| Net Foreign Currency Exchange Gain Loss | $-48,000 | $-154,000 | $34,000 | $384,000 |
| Net Income From Continuing Operations | $-95,059,000 | $-88,447,000 | $-84,713,000 | $-97,090,000 |
| Net Intangibles Purchase And Sale | - | - | $0 | $-195,000 |
| Purchase Of Intangibles | - | - | $0 | $-195,000 |
| Other Non Cash Items | - | - | $86,000 | $700,000 |
| Repayment Of Debt | - | - | - | $0 |
| Issuance Of Debt | - | - | - | $0 |
| Interest Paid Supplemental Data | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |